

May 19, 2021

---

## Glaxo's Covid-19 effort progresses, this time thanks to Medicago



[Amy Brown](#)

Glaxosmithkline, one of the world's largest vaccine makers but absent from the first wave of Covid-19 jabs, confirmed this week that it has a chance of playing a role in the tail of the pandemic. Two novel vaccines are now at the pivotal stage. The first is partnered with Sanofi and the second with Medicago, with Glaxo providing the adjuvant for both. These projects are being developed with the market for booster shots in mind. High immune response after a single dose in patients with prior infection shows strong booster potential, Sanofi and Glaxo said of their candidate. Canada's Medicago, which released phase 2 data yesterday, pointed to strong neutralising antibody responses and the potential for a potent, adjuvanted vaccine to provide cross-protection against emerging variants. The biggest challenge for these efforts arguably lies in recruiting patients for placebo-controlled phase 3 trials in regions where existing vaccines are readily available; the developers have laid out seemingly ambitious predictions for progress, with both promising data well before the end of this year. Glaxo also has a stake in two other major pending vaccine readouts, from Curevac and Novavax, so the UK pharma giant will enter the front line of the pandemic sooner or later.

## Glaxo's Covid-19 vaccine efforts... and other second-wave projects

Project	Description	Developer(s)	Update
<b>With Glaxo involvement...</b>			
CoVLP	Plant-derived coronavirus-like particle (2 doses)	Medicago/Glaxo	<a href="#">Ph2 data published via preprint; Ph3 started Mar 2021 enrolling in Canada, US, UK, Brazil</a>
Covid-19 vaccine project	Recombinant protein (2 doses)	Sanofi/Glaxo	<a href="#">Ph2 data shows strong immune responses (PR only); Ph3 to start mid-year.</a>
CVnCoV	mRNA (2 doses)	Curevac (Glaxo to support manufacturing and co-develop next-gen multi-valent candidates)	<a href="#">Herald</a> , Europe ph3, due to report Q2'21; <a href="#">preclinical data published on next-gen project (preprint)</a> .
NVX-CoV2373	Recombinant nanoparticle (2 doses)	Novavax (Glaxo to support manufacture of 60m doses for UK)	<a href="#">Data reported from UK ph3 &amp; S Africa ph2b trials; US/Mexico ph3 data due Q2 2021</a>
GBP510	Nanoparticle (2 doses)	SK Bioscience (Glaxo providing adjuvant)	<a href="#">Phase 1/2 ongoing.</a>
<b>Other second wave projects...</b>			
Covaxin	Inactivated virus (2 doses)	Bharat Biotech/Ocugen	<a href="#">Data from ph3 India trial reported Apr 2021</a>
Ad5-nCoV	Adenovirus type 5 (1 dose)	Cansino Biologics	<a href="#">Ph3 recruiting in Russia &amp; S America</a>
ZyCoV-D	DNA (3 doses)	Zydus Cadila	<a href="#">Ph3 ongoing in India</a>
COVID-19 S-Trimer	Trimerised fusion protein (2 doses)	Clover/Dynavax	<a href="#">Ph2/3 OUS Spectra trial started Mar 2021</a>
VLA2001	Inactivated virus (2 doses)	Valneva/Dynavax	<a href="#">Ph3 UK Cov-Compare study</a> vs Astra's Vaxzevria started Apr 2021
INO-4800	DNA (2 doses)	Inovio	Ph2 data disappointed ( <a href="#">preprint</a> ); <a href="#">Ph3 due to start in Q2 2021, pending lifting of FDA hold</a>
ARCT-021	Self-amplifying mRNA (1 dose)	Arcturus	<a href="#">Ph3 planned for Q2 2021 pending results from ph2 trial</a>

*Note: includes notable projects already progressed into phase 2/3 development or likely to do so imminently. List not exhaustive. Source: Evaluate Pharma & company statements.*

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas  
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2022 Evaluate Ltd.